NEWSROOM

MEDIA CONTACTS

media@galderma.com

Christian Marcoux, Chief Communications Officer: +41 76 315 26 50

Sébastien Cros, Corporate Communications Director: +41 79 529 59 85

Galderma successfully completes acquisition of ALASTIN Skincare®

Addressing gaps in acne management: New expert recommendations to optimize patient care

Maria Teresa Hilado to join Galderma’s Advisory Committee

Galderma announces new data demonstrating the positive anti-inflammatory effect and mode of action of nemolizumab in patients with moderate to severe Prurigo Nodularis

Galderma to acquire award-winning ALASTIN Skincare® enhancing its integrated dermatology platform to continue delivering the best experience to patients

RESTYLANE®, the original stabilized hyaluronic acid filler, celebrates 25 years of unmatched achievement

Galderma presents new nemolizumab data at EADV reinforcing rapid onset of action and consistent relief of symptoms for people with prurigo nodularis and atopic dermatitis

Galderma to unveil ground-breaking data from across its leading dermatology portfolio and showcase major update for sensitive skincare brand CETAPHIL® at the 2021 EADV Congress

Galderma and CETAPHIL® Announce Renewed Commitment to Environmental Sustainability and Social Impact Through New Clear Skies Initiative

Galderma announces exclusive agreement with Sofregen to develop the next generation of biostimulator fillers using silk-based technology

Galderma to present new data from leading aesthetics portfolio and launch RESTYLANE® EYELIGHT™ at AMWC 2021

Sol-Gel Technologies and Galderma announce exclusive licenses for the commercialization of EPSOLAY® and TWYNEO® in the United States

Alluzience®, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe

What are you looking for?

Galderma Global

NEWSROOM

MEDIA CONTACTS

Filter news by date

Galderma successfully completes acquisition of ALASTIN Skincare®

Addressing gaps in acne management: New expert recommendations to optimize patient care

Maria Teresa Hilado to join Galderma’s Advisory Committee

Galderma announces new data demonstrating the positive anti-inflammatory effect and mode of action of nemolizumab in patients with moderate to severe Prurigo Nodularis

Galderma to acquire award-winning ALASTIN Skincare® enhancing its integrated dermatology platform to continue delivering the best experience to patients

RESTYLANE®, the original stabilized hyaluronic acid filler, celebrates 25 years of unmatched achievement

Galderma presents new nemolizumab data at EADV reinforcing rapid onset of action and consistent relief of symptoms for people with prurigo nodularis and atopic dermatitis

Galderma to unveil ground-breaking data from across its leading dermatology portfolio and showcase major update for sensitive skincare brand CETAPHIL® at the 2021 EADV Congress

Galderma and CETAPHIL® Announce Renewed Commitment to Environmental Sustainability and Social Impact Through New Clear Skies Initiative

Galderma announces exclusive agreement with Sofregen to develop the next generation of biostimulator fillers using silk-based technology

Galderma to present new data from leading aesthetics portfolio and launch RESTYLANE® EYELIGHT™ at AMWC 2021

Sol-Gel Technologies and Galderma announce exclusive licenses for the commercialization of EPSOLAY® and TWYNEO® in the United States

Alluzience®, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe

NEWSROOM

MEDIA CONTACTS

Filter news by date

Galderma successfully completes acquisition of ALASTIN Skincare®

Addressing gaps in acne management: New expert recommendations to optimize patient care

Maria Teresa Hilado to join Galderma’s Advisory Committee

Galderma announces new data demonstrating the positive anti-inflammatory effect and mode of action of nemolizumab in patients with moderate to severe Prurigo Nodularis

Galderma to acquire award-winning ALASTIN Skincare® enhancing its integrated dermatology platform to continue delivering the best experience to patients

RESTYLANE®, the original stabilized hyaluronic acid filler, celebrates 25 years of unmatched achievement

Galderma presents new nemolizumab data at EADV reinforcing rapid onset of action and consistent relief of symptoms for people with prurigo nodularis and atopic dermatitis

Galderma to unveil ground-breaking data from across its leading dermatology portfolio and showcase major update for sensitive skincare brand CETAPHIL® at the 2021 EADV Congress

Galderma and CETAPHIL® Announce Renewed Commitment to Environmental Sustainability and Social Impact Through New Clear Skies Initiative

Galderma announces exclusive agreement with Sofregen to develop the next generation of biostimulator fillers using silk-based technology

Galderma to present new data from leading aesthetics portfolio and launch RESTYLANE® EYELIGHT™ at AMWC 2021

Sol-Gel Technologies and Galderma announce exclusive licenses for the commercialization of EPSOLAY® and TWYNEO® in the United States

Alluzience®, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe

Confirm navigation